ArticleJournal of animal science2026
Characterization of the inflammatory response of a canine intestinal epithelial cell line challenged with lipopolysaccharides and/or butyrate.
Article in Journal of animal science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Barrier and Immune Modulation byInternational journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cell culture models are used to assess the impacts that dietary changes have on host health; however, there is limited knowledge about canine intestinal cell models compared to those for humans. The objective of this study was to use a canine intestinal epithelial cell (cIEC) line to investigate responses to pro- and anti-inflammatory treatments relevant to health in the dog. It was anticipated that lipopolysaccharides (LPS) would cause a pro-inflammatory response, while butyrate would cause an anti-inflammatory response and mitigate the pro-inflammatory response induced by LPS. cIEC were stimulated with 250 µg/mL of LPS, 1 mM of butyrate, or a combination of LPS and butyrate compared to untreated controls over 8 h (n = 6 per treatment group). LPS treatment significantly reduced transepithelial electrical resistance (TEER) over time and caused increases in the protein abundance and gene expression of the pro-inflammatory interleukin (IL)-8 and chemokine (C-C motif) ligand (CCL)2 compared to untreated controls. Additionally, LPS treatment caused increases in the gene expression of the pro-inflammatory interferon gamma-induced protein (IP)-10, and increased protein abundances of keratinocyte chemotactic (KC)-like in apical and basal cell media compared to untreated cIEC. Butyrate failed to elicit an increase in anti-inflammatory cytokines, although treatment significantly reduced protein expression of the pro-inflammatory CCL2 in apical cell culture media and increased protein expression of IP-10. Butyrate reduced the LPS-induced IL-8 and KC-like increased pro-inflammatory protein abundances in basal cell culture media compared to untreated canine IEC and was found to reduce the LPS-induced intestinal barrier hyperpermeability. However, butyrate and LPS in combination caused an increase in CCL2 gene expression compared to treatment with butyrate and LPS alone. Therefore, this study has shown that butyrate can mitigate some aspects of the LPS-induced inflammatory response in an in vitro model of the canine intestine. Overall, changes in intestinal barrier integrity in response to the treatment were similar to that reported for human cell models; however, the molecular signaling somewhat differed, highlighting the need for further studies and illustrating the value of studying a canine cell model to understand the molecular responses in the dog.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.